Literature DB >> 12171505

Current prodrug strategies via membrane transporters/receptors.

Banmeet S Anand1, Surajit Dey, Ashim K Mitra.   

Abstract

Prodrug design strategies have been employed to improve the delivery of drugs with undesirable pharmacokinetic properties such as chemical stability and lack of specificity. Targeted prodrug design represents a new strategy for site-directed and efficient drug delivery. Targeting of drugs to transporters and receptors to aid in site-specific carrier-mediated absorption is emerging as a novel and clinically significant approach. Various prodrugs have been successful in achieving the goals of enhanced bioavailability and are, therefore, considered to be an important tool in biopharmaceutics. This review highlights the advances in prodrug design targeted towards membrane transporters/receptors in the past few years.

Mesh:

Substances:

Year:  2002        PMID: 12171505     DOI: 10.1517/14712598.2.6.607

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  15 in total

Review 1.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

Review 2.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  Mitochondrial expression and activity of P-glycoprotein under oxidative stress in outer blood-retinal barrier.

Authors:  Yue-Hong Zhang; Juan Li; Wei-Zhong Yang; Zhuan-Hua Xian; Qi-Ting Feng; Xiang-Cai Ruan
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

Review 4.  Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery.

Authors:  Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2012-06       Impact factor: 3.465

Review 5.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

Review 6.  A comprehensive insight on ocular pharmacokinetics.

Authors:  Vibhuti Agrahari; Abhirup Mandal; Vivek Agrahari; Hoang M Trinh; Mary Joseph; Animikh Ray; Hicheme Hadji; Ranjana Mitra; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

7.  Molecular expression and functional activity of efflux and influx transporters in hypoxia induced retinal pigment epithelial cells.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; V K Chaithanya Ponnaluri; Dhananjay Pal; Mridul Mukherji; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-07-01       Impact factor: 5.875

8.  The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.

Authors:  Yasuhiro Tsume; Tuba Incecayir; Xueqin Song; John M Hilfinger; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2013-12-19       Impact factor: 5.571

9.  Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells--novel strategies for intracellular drug targeting.

Authors:  Megha Barot; Mitan R Gokulgandhi; Dhananjay Pal; Ashim K Mitra
Journal:  Exp Eye Res       Date:  2012-10-29       Impact factor: 3.467

10.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.